Background. The prevalence of detectable viremia has previously been used to infer the potential for ongoing human immunodeficiency virus (HIV) transmission. To date, no study has evaluated the longitudinal change in the prevalence of detectable viremia within the HIV-positive community (PDV+) and the entire population (PDV P ) using data from a sub-Saharan African setting.
By 2015, almost half of the 36.7 million people living with human immunodeficiency virus (HIV) were on combination antiretroviral therapy (ART) [1] . ART is expected to prevent the onward transmission of HIV by reducing the number of infected persons with detectable viremia [2, 3] . For this reason, the HIV-positive prevalence of detectable viremia (PDV+), which is the proportion of all infected persons with a recent viral load above a copies/mL threshold, has been promoted as a sensitive biological index of ART program effectiveness. The PDV+ has previously been used to monitor a community's uptake of ART [4, 5] , and is central to the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 targets to have 90% of all ART-initiated patients achieve undetectable viremia by the year 2020 [6] . In addition, the PDV+ has been used to quantify the potential for ongoing HIV transmission within a well-defined community or geographic area [4, 5, [7] [8] [9] . An assumption underlying the use of this measure is that higher levels of ART coverage will lower the PDV+ and thus reduce the incidence of HIV infection within the general population.
However, one key limitation of the PDV+ is that it does not account for the relative sizes of the HIV-infected and HIVuninfected populations [10] . This information is important because the risk of acquiring HIV will depend not only on the number of infected persons with detectable viremia (ie, PDV+) but also on the number of infected persons in the general population (ie, HIV prevalence), and the rate of sexual contact between them [10] . Thus, an improved biological index, which we call the population prevalence of detectable viremia (PDV P ) [11] , can be obtained by multiplying the PDV+ with the HIV prevalence (see Supplementary Figure 1 ). Aggregated viral load indices that account for the HIV prevalence have gained traction in the literature [12] [13] [14] [15] , and we recently showed that the PDV P is significantly better than the PDV+ at predicting the prospective risk of HIV infection [11] .
As far as we know, time trends in both the PDV+ and the PDV P have not been evaluated and compared using data from a sub-Saharan African population. In 2011, 2013, and 2014, we obtained 6752 HIV-positive and 15 415 HIV-negative test results from a population-based surveillance system in the KwaZuluNatal province of South Africa. We quantified the PDV+ as the proportion of the HIV-positive test results with a viral load >1550 copies/mL and then quantified the PDV P as the proportion of the HIV-positive and HIV-negative test results with a viral load >1550 copies/mL. Using this population-based data, we had a unique opportunity to empirically estimate and compare the changes in both the PDV+ and PDV P measures over time.
METHODS

Setting
The Africa Health Research Institute (AHRI) maintains a population-based surveillance system in the Umkhanyakude district of the northern KwaZulu-Natal province. Most of the surveillance area is poor and rural, with several informal periurban settlements and a single urban township [16] . The area is 438 km 2 in size with a population of approximately 90 000 people and 11 000 households.
HIV Surveillance Survey
AHRI has collected longitudinal data on households and individuals within the surveillance area since 2000. Every 6 months, trained field workers visit a key informant within the household to collect information on both resident and nonresident members. Biannual participation rates for household data collection are typically >95%. Nested within the AHRI cohort is the population-based HIV cohort. Field workers have visited households every 12 months since 2004 and identified eligible participants >15 years of age for HIV testing. After obtaining consent, the field workers extract blood according to the UNAIDS and World Health Organization Guidelines for Using HIV Testing Technologies in Surveillance. Of the eligible participants contacted, 78% agreed to be tested for HIV at least once in the 3 survey years. Participants from the AHRI and HIV cohorts were linked across the survey years and the data were stored in a SQL database server. The AHRI and HIV cohorts are described in greater detail elsewhere [16] .
HIV Incidence and ART Usage
The AHRI surveillance area is situated at the epicenter of the global AIDS epidemic. [18] . The increase in HIV prevalence has been attributed to ART-associated reductions in mortality [19] .
ART can be accessed for free at any of the 17 primary healthcare clinics within or adjacent to the surveillance area [20] to quantify the viral load levels. As described in greater detail elsewhere [21] , the quantification method has a lower detection limit of 1550 copies/mL. Due to insufficient specimens, we had to exclude 770 (10.24%) viral load samples. For the final analysis, we therefore used a total of 6752 viral load measurements from 4991 unique participants who tested HIV positive in 2011 (n = 2366), 2013 (n = 2135), and 2014 (n = 2251).
Prevalence of Detectable Viremia Measures
We calculated the PDV+ for each survey year t as follows (we drop the subscript t as it is implicit throughout). Let v i denote the i th viral load measurement for i n = ¼ We note that the number of HIV-negative test results for each survey year was determined with n n n H H as as as as as
where H is the HIV prevalence and the subscripts a and s denote the age group and sex, respectively. Overall, 15 415 HIV-negative test results were sampled from 11 522 unique participants. We used this proportional allocation approach [22] to determine n -because 770 HIV-positive samples were excluded from the analysis due to insufficient specimens (as described in the previous section). Otherwise, we would underestimate the PDV P if we did not sample the correct n -using this approach.
Statistical Analysis
We performed summary statistics for the unadjusted and age-and sex-adjusted PDV+, PDV P , and HIV prevalence measures by year. To statistically assess the change in the PDV+ and PDV P measures over time, we used a generalized estimating equation (GEE) model with a logit link function. We chose a GEE model because 32.4% of the participants tested HIV positive in >1 survey year. We fitted 4 regression models using data from the HIV-positive participants only (ie, PDV+) and from the HIV-positive and HIVnegative participants (ie, PDV P ). We observed marked differences in the adjusted PDV+ and PDV P measures by sex over time, as shown in Figure 2 . Between 2011 and 2014, the PDV+ for women decreased by 16.5 pp, from 71.8% to 55.3%, compared with a 10.6 pp decrease in the PDV+ for men, from 77.80% to 67.18% (Supplementary Table 1 ). However, women had a higher HIV prevalence, 30.56% in 2011 and 35.61% in 2014, and therefore a higher PDV P , which decreased by 2.1 pp, from 21.35% to 19.23% over the survey (Table 2 ). In addition, the odds of detectable viremia was significantly lower in women than men, but there was no difference between men and women over time, as shown by the 2 interaction terms in Table 2 (Table 3) . Although the odd of detectable viremia was higher for women, these odds declined significantly over time when compared with men. We found a similar result when we stratified our analysis by sex (Supplementary Table 2 ).
DISCUSSION
Our study has quantified the temporal change in the HIVpositive prevalence of detectable viremia (PDV+) and the population prevalence of detectable viremia (PDV P ) using data from a sub-Saharan African population. The results show that the PDV+ decreased by almost 14 percentage points (PP), from 73.8% to 59.9%, over the 2011-2014 survey period. In this regard, the 17 healthcare clinics within or adjacent to our surveillance area have been effective in getting HIV-infected persons onto ART and then reducing their viral load levels over time. This is positive news for the global HIV treatment-as-prevention initiative as well as for our study community, which is considered to be at the epicentre of the global AIDS epidemic.
We compare our 40.1% prevalence of undetectable viremia in the HIV-positive community (ie, 100 -PDV+) in 2014 with population-based studies undertaken in Malawi [23] , Zambia [24] , and Zimbabwe [25] in 2015-2016. In Malawi, the prevalence of undetectable viremia (<1000 copies/mL) in the HIV-positive community was 67.6% (95% CI, 65.0%-70.2%) among 15-to 64-year-olds, 59.8% (95% CI, 57.4%-62.2%) among 15-to 59-year-olds in Zambia, and 60.4% (95% CI, 58.3%-62.5%) among 15-to 64-year-olds in Zimbabwe. These estimates are markedly higher than our PDV+ result, despite a lower detection level. It is likely that these differences would be slightly smaller in 2015-2016, if our PDV+ continued to decrease as it did over the survey period. Nevertheless, we acknowledge that our 40.1% estimate is well below the UNAIDS target of 73% (ie, 90 90 90´) to be achieved by 2020.
In addition to quantifying a community's exposure to ART, the PDV+ has also been used to infer the potential for ongoing HIV transmission at the population level [2] [3] [4] [5] 7] . However, measures such as the PDV+ have been criticized by Miller et al [10] and others [11] [12] [13] [14] [15] because they do not account for the relative sizes of the infected and uninfected populations (ie, HIV prevalence). Following this work, we multiplied the PDV+ by the HIV prevalence to construct a measure called the population prevalence of detectable viremia (PDV P ) [11] . This measure enabled us to account for the high HIV prevalence in the AHRI study area, which increased from 26.7% to 32.4% over the 2011-2014 period. Our results show that the steady rise in the HIV prevalence offset the gains made by the declining PDV+. Thus, the PDV P only decreased by <1 pp, from 18.8% in 2011 to 17.9% in 2014.
We also observed significant differences in the PDV+ and PDV P measures by sex over time. For example, the PDV+ for women decreased by 16.5 pp between 2011 and 2014, from 71.8% to 55.3%, when compared with a decrease of 10.6 pp for men, from 77.8% to 67.2%. Previous research has shown that women have more frequent contact with the healthcare system, due in large part to their antenatal treatment and care needs, where they can initiate ART early and have their viral loads monitored [26, 27] . However, because women had a higher HIV prevalence, they also had a higher overall PDV P , which decreased by 2.1 pp, from 21.3% to 19.2%, over the survey period. Importantly, we found that men had a greater increase in their HIV prevalence over time, which offset the decline in their PDV+. Thus, the PDV P for men actually increased by 1.6 pp, from 14.6% in 2011 to 16.2% in 2014. We have previously exploited the substantial space-time heterogeneity in ART scale-up over 8 years to demonstrate independent reductions in the individual risk of HIV acquisition with increasing ART exposure [17, 28, 29] . In more recent work, we used viral load survey data from 2011 to show that the prospective risk of HIV acquisition (5 years of follow-up) was independently associated with the PDV P (adjusted hazard ratio [aHR], 1.07, P < .001) but not the PDV+ (aHR, 1.005, P = .4) [11] . Barring substantial changes in sexual behavior, one might expect that the minimal change in the PDV P would translate into a minimal change in the crude HIV incidence rate. In this regard, we report elsewhere that the crude HIV incidence rate has been relatively stable in the AHRI study population between 2008 and 2016 [30, 31] . Thus, at an ecological level, the HIV incidence rate corresponds with the PDV P , rather than declining in relation to the marked decrease in the PDV+. These findings, and the results from our earlier work [11] , provide further empirical support for the PDV P 's utility as a measure of the potential for HIV transmission.
The PDV P will not capture all the fundamental phenomena that underlie HIV transmission dynamics within a population. To better quantify the potential for HIV transmission, it would be ideal to use population-based surveillance systems to collect information on the number and patterns of condomless sex acts. But reliable self-report data is often difficult to obtain, and not all countries will have population-based surveillance systems, which are costly to establish and maintain. Public healthcare facilities can be a more affordable and convenient source of data. However, 2 recent studies have shown that facility-based PDV+ measures are poor indicators of the incidence of HIV infection [11, 12] .
One potential limitation of the study is that 22% of the participants refused to take an HIV test during the survey period. In a previous study, Larmarange et al [32] found that HIV-infected participants were significantly less likely than HIV-uninfected participants to consent to an HIV test during a single survey round. This refusal rate could potentially bias both the HIV prevalence and PDV P measures downward. However, 2 recent studies have confirmed that survey nonparticipation in this community did not lead to large biases in the cross-sectional estimation of the HIV prevalence [33, 34] . Furthermore, it is unlikely that the 22% refusal rate would bias the PDV + measure, as viral load measurements were obtained from all of the HIVpositive test results.
The PDV+ has been promoted as a proxy for ART program effectiveness. In recent years, it has gained traction in light of the UNAIDS target to have 90% of all ART-initiated persons achieve and maintain undetectable viremia by the year 2020 [6] . But while the PDV+ may reflect an infected community's exposure to ART, it may not tell us enough about the potential for HIV transmission within the general population. Recent work has therefore begun to promote the PDV P as a more sensitive biological measure for this purpose, primarily because it accounts for the underlying prevalence of HIV [10] [11] [12] [13] [14] [15] . We therefore highlight the need for countries to monitor and report the prevalence of detectable viremia among all adults, irrespective of HIV status.
